Further to a six-month option granted by MGI Pharma to Japanese firm Dainippon Pharmaceutical earlier this year relating to MGI's acylfulvenes (Marketletter May 8), Dainippon has been granted exclusive rights in Japan to the product. Under the terms of the deal, MGI will receive $12 million in milestone payments during the precommercial phase and will supply Dainippon with bulk drug substance.
Acylfulvenes have potential to become effective anticancer therapies, according to MGI. In animal studies, these compounds have been shown to be unusually effective against cancer of the lung, breast, colon and skin. An Investigational New Drug application was filed in the USA in September. Human testing of the compounds should start before the end of this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze